Summit Therapeutics Inc. — Director's Dealing 2020

Nov 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2020-11-06

Reporting Person: DUGGAN ROBERT W (Director, Chief Executive Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-06	Common Stock	P	14071856	$3.34	Acquired	56296533	Direct

Footnotes

F1: Represents the number of shares of Common Stock that the Reporting Person purchased in a private placement at a price of $3.34 per share pursuant to a Securities Purchase Agreement, dated October 2, 2020, by and between the Reporting Person and the Issuer (the "Purchase Agreement"). Pursuant to the Purchase Agreement, the Issuer directed the Reporting Person to purchase 14,071,856 shares of Common Stock.